Balyasny Asset Management
TRDA icon

Balyasny Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Balyasny Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,017
Closed -$144K – 3536
2025
Q4 		$144K Buy
+14,017
New +$118K ﹤0.01% 2927
2023
Q1 		– Sell
-12,132
Closed -$164K – 3162
2022
Q4 		$164K Buy
+12,132
New +$213K ﹤0.01% 2170

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's TRDA Position: Q1 2026 in Review

Balyasny Asset Management sold out of Entrada Therapeutics (TRDA) in Q1 2026, closing a stake of 14,017 shares — an estimated $144K sold.

Balyasny Asset Management first reported a position in TRDA in Q4 2022 and held it in 2 quarters. The position peaked at $164K in Q4 2022. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Balyasny Asset Management reported no remaining Entrada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 14,017 Entrada Therapeutics shares in Q1 2026, an estimated $144K.
  • Balyasny Asset Management first reported a position in Entrada Therapeutics in Q4 2022 and held it in 2 quarters.
  • Balyasny Asset Management's Entrada Therapeutics position peaked at $164K in Q4 2022.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.